CTOs on the Move

DirectRx

www.directrx.com

 
DirectRx is an independent pharmacy dedicated to providing patients with unparalleled, personalized pharmaceutical care. At DirectRx Pharmacy, the patient, physician and pharmacy form a circle of integrated services and coordinated care. There are no gaps in patient care between physician and pharmacy, because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our sense of urgency and commitment to unparalleled customer care makes DirectRx unique in the marketplace. We are large enough to provide the full range of pharmaceutical solutions and medications required to optimally treat chronic disease states, yet small enough to care that each ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.directrx.com
  • 830 Kirts Boulevard Suite 300
    Troy, MI USA 48084
  • Phone: 855.362.3397

Executives

Name Title Contact Details

Similar Companies

Meadow Lane Pharmacy

Meadow Lane Pharmacy is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioAssist

BioAssist is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

TFF Pharmaceuticals

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.